--The U.S. Food and Drug Administration (FDA) said it had completed its inspection of a U.S. plant that makes Johnson & Johnson and AstraZeneca's COVID-19 vaccine and asked for remediation of issues including peeling paint and loose debris at the site.
--The FDA's inspection closeout report, also known as "FDA Form 483", cited observations including failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca.
--to date, no vaccine manufactured at this plant has been distributed for use in the United States.
Search "U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine" from Reuters to find the source.
--The FDA's inspection closeout report, also known as "FDA Form 483", cited observations including failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson and AstraZeneca.
--to date, no vaccine manufactured at this plant has been distributed for use in the United States.
Search "U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine" from Reuters to find the source.
